What are the indications, dosing regimen, monitoring requirements, and contraindications for using tofacitinib in a patient with ankylosing spondylitis?

Tofacitinib for Ankylosing Spondylitis

Tofacitinib 5 mg twice daily is FDA-approved and effective for active ankylosing spondylitis, but should be reserved as a second-line option after TNF inhibitors and IL-17 inhibitors due to safety concerns, particularly cardiovascular and thromboembolic risks in patients over 50 with cardiovascular risk factors. 1

Indications

Tofacitinib is indicated for adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to NSAIDs 1. The 2023 Pan American League of Associations for Rheumatology (PANLAR) guidelines specifically recommend JAK inhibitors like tofacitinib when biologic DMARDs (TNF inhibitors or IL-17 inhibitors) are contraindicated or unavailable 2. The guideline explicitly states that TNF inhibitors and IL-17 inhibitors should be considered first, with JAK inhibitors reserved for situations where biologics cannot be used 2.

This positioning reflects the greater long-term safety data available for biologics and concerns about JAK inhibitor safety profiles, particularly from the ORAL Surveillance study showing increased cardiovascular and thromboembolic events 3.

Dosing Regimen

The FDA-approved dose is tofacitinib 5 mg orally twice daily 1. This dosing was validated in both Phase 2 and Phase 3 trials 4.

Key dosing considerations:

• Do not exceed 5 mg twice daily - higher doses (10 mg twice daily) are not approved for ankylosing spondylitis and carry increased safety risks 1
• No loading dose is required
• Clinical response typically begins at 4-8 weeks, which is slower than TNF inhibitors 3
• Peak ASAS20 response rates reach approximately 56-80% by week 16 4, 5

Dose Modifications for Special Populations

Renal impairment:

• Moderate impairment (CrCl 30-49 mL/min): reduce to 5 mg once daily
• Severe impairment (CrCl <30 mL/min): not recommended 1

Hepatic impairment:

• Moderate impairment (Child-Pugh B): reduce to 5 mg once daily
• Severe impairment (Child-Pugh C): avoid use 1

Drug interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole): reduce to 5 mg once daily
• Moderate CYP3A4 inhibitors with strong CYP2C19 inhibitors: reduce to 5 mg once daily 1

Monitoring Requirements

Before Initiating Treatment

Mandatory screening:

• Tuberculosis screening - tuberculin skin test or interferon-gamma release assay, chest X-ray if positive 1
• Hepatitis B and C screening - surface antigen, core antibody, and viral load if positive 1
• Complete blood count - establish baseline hemoglobin, lymphocytes, neutrophils 1
• Lipid panel - baseline cholesterol levels 1
• Liver function tests - baseline ALT, AST 1

During Treatment

Laboratory monitoring schedule:

• At 4-8 weeks after initiation, then every 3 months:
  • Complete blood count (hemoglobin, absolute lymphocyte count, absolute neutrophil count)
  • Liver enzymes (ALT, AST)
  • Lipid panel 1

Interrupt treatment if:

• Absolute lymphocyte count <500 cells/mm³
• Absolute neutrophil count <1000 cells/mm³
• Hemoglobin <8 g/dL
• ALT or AST >3× upper limit of normal 1

Clinical monitoring:

• Assess for signs/symptoms of infection at each visit
• Monitor for new skin lesions (malignancy risk)
• Cardiovascular risk assessment, particularly in patients ≥50 years with ≥1 cardiovascular risk factor 1

Contraindications

Absolute Contraindications

Do not use tofacitinib in patients with:

• Active serious infections, including localized infections 1
• Known hypersensitivity to tofacitinib or any excipient 1

Black Box Warnings (Use with Extreme Caution or Avoid)

The FDA label carries five black box warnings that effectively function as strong relative contraindications 1:

1. Serious infections - increased risk of bacterial, mycobacterial, invasive fungal, viral, and opportunistic infections. Avoid in active infection 1

2. Mortality - increased all-cause mortality in patients ≥50 years with ≥1 cardiovascular risk factor (data from rheumatoid arthritis ORAL Surveillance trial) 1

3. Malignancy - increased risk of lymphoma and other malignancies. Avoid in patients with current or history of malignancy except adequately treated non-melanoma skin cancer 1

4. Major adverse cardiovascular events (MACE) - increased risk of cardiovascular death, myocardial infarction, and stroke in patients ≥50 years with ≥1 cardiovascular risk factor. This is the most critical consideration when choosing tofacitinib over biologics 1

5. Thrombosis - increased risk of deep venous thrombosis and pulmonary embolism, particularly in patients ≥50 years with ≥1 cardiovascular risk factor 1

Strong Relative Contraindications

• Age ≥50 years with cardiovascular risk factors (current/former smoker, hypertension, diabetes, dyslipidemia, coronary artery disease, family history)
• History of thromboembolic events
• Active or latent tuberculosis (treat latent TB before starting)
• Chronic viral hepatitis
• Diverticulitis or gastrointestinal perforation risk
• Lymphopenia (<500 cells/mm³), neutropenia (<1000 cells/mm³), or anemia (<9 g/dL) 1

Efficacy Data

The Phase 3 trial demonstrated significant efficacy at week 16 4:

• ASAS20 response: 56.4% vs 29.4% placebo (p<0.0001)
• ASAS40 response: 40.6% vs 12.5% placebo (p<0.0001)
• Improvements in ASDAS-CRP, BASDAI, BASFI, and MRI inflammation
• Benefits maintained through 48 weeks of open-label treatment

Safety Profile in Ankylosing Spondylitis

In the pooled Phase 2/3 AS trials through 48 weeks 6:

• No deaths, opportunistic infections, tuberculosis, malignancies, MACE, or thromboembolic events occurred
• Serious infection rate: 0.3% (1 case of aseptic meningitis)
• Herpes zoster: 1.7% (mostly non-serious, one multi-dermatomal case)
• Most common adverse events: nasopharyngitis, upper respiratory infections

Critical caveat: These favorable AS-specific safety data come from relatively short trials (≤48 weeks) in younger patients without significant cardiovascular risk factors. The black box warnings are based on longer-term data from older rheumatoid arthritis populations 1, 7.

Clinical Algorithm for Use

Step 1: Patient has active AS (ASDAS-CRP ≥2.1 or BASDAI ≥4) despite adequate NSAID trial

Step 2: Assess for contraindications

• Age ≥50 with cardiovascular risk factors → prefer TNF/IL-17 inhibitors
• History of malignancy, thrombosis, serious infection → prefer TNF/IL-17 inhibitors
• TNF/IL-17 inhibitors contraindicated or unavailable → consider tofacitinib

Step 3: If tofacitinib appropriate, complete pre-treatment screening (TB, hepatitis, CBC, LFTs, lipids)

Step 4: Initiate tofacitinib 5 mg twice daily (adjust for renal/hepatic impairment or drug interactions)

Step 5: Monitor CBC, LFTs, lipids at 4-8 weeks, then every 3 months

Step 6: Assess response at 12-16 weeks

• ASAS20 response or ASDAS improvement ≥1.1 → continue
• Inadequate response → switch to different mechanism (TNF or IL-17 inhibitor) 2

Common Pitfalls

1. Using tofacitinib as first-line therapy - Guidelines clearly position it after biologics due to safety concerns 2

2. Inadequate cardiovascular risk assessment - The MACE and thrombosis risks in patients ≥50 with risk factors are real and should shift decision-making toward biologics 1

3. Insufficient infection screening - Always screen for TB and hepatitis before starting; failure to do so risks reactivation 1

4. Expecting rapid response - Unlike TNF inhibitors that may work within 2 weeks, tofacitinib typically requires 4-8 weeks for clinical benefit 3

5. Inadequate laboratory monitoring - Cytopenias and liver enzyme elevations can occur; monitor CBC and LFTs regularly 1

6. Combining with biologics without evidence - While one case series suggests dual therapy may be feasible 8, this is not standard practice and lacks safety data

7. Using in patients with diverticulitis history - Risk of gastrointestinal perforation, though rare, is a concern 1